Recombiplastin 2g kit

Blood counts were analyzed using a hematology analyzer (Siemens Healthineers, Germany). Serum glucose, creatinine, and urea were analyzed using standard laboratory methods (Cobas c501, Roche Diagnostics, Mannheim, Germany). Coagulological determinations were performed on an ACL TOP 300 CTS Coagulation Analyzer (Instrumentation Laboratory, Werfen Headquarters, Barcelona, Spain). The international normalized ratio (INR) was determined using the RecombiPlasTin 2G kit from Instrumentation Laboratory and the activated partial thromboplastin time (APTT) was determined using the APTT-SP kit, also from Instrumentation Laboratory. The direct potentiometric measurement of potassium in blood serum was performed with a liquid ion-exchange electrode.

Clinical chemistry routine parameters were available for each patient. Creatinine and bilirubin serum concentrations were determined by the application of enzymatic assay creatinine Plus Ver. 2 and Bilirubin Total DPD Gen.2 kit (both kits purchased from Roche, Mannheim, Germany), respectively according to manufacturer’s instructions. Both assays ran on the Cobas 6000 and 8000 analyzers (Roche, Mannheim, Germany). The RecombiPlasTin 2G kit (Instrumentation Laboratory, Lexington, USA) was used to determine the INR from citrated plasma using an ACL TOP 700 System (Instrumentation Laboratory, Lexington, USA).
MELD score was calculated according to the guidelines of the UNOS [12 ] using the following formula:
$MELD score=10 * \left(0.957 * ln\left(creatinine \left[mg/dl\right]\right)+0.378 * ln\left(bilirubin \left[mg/dl\right]\right)+1.12 * ln\left(INR\right) + 0.643\right)$
According to the guidelines, determined creatinine concentrations below 1.0 mg/dl or above 4.0 mg/dl were set on the defined minimum of 1.0 mg/dl or on the defined maximum of 4.0 mg/dl, respectively. The MELD score range is defined from 6 to 40.

Blood counts were determined using an automated standard hematology analyzer (Siemens Healthineers, Germany). Serum glucose, creatinine, and urea were analyzed using standard laboratory methods (Cobas c501, Roche Diagnostics, Mannheim, Germany). Coagulological determinations were estimated on an ACL TOP 300 CTS Coagulation Analyzer (Instrumentation Laboratory, Werfen Headquarters, Barcelona, Spain). The international normalized ratio (INR) was assayed using the RecombiPlasTin 2G kit from Instrumentation Laboratory and the activated partial thromboplastin time (APTT) was estimated using the APTT-SP kit, also from Instrumentation Laboratory. The direct potentiometric measurement of potassium in blood serum was measured with a liquid ion-exchange electrode.